Harini Adivikolanu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Harini Adivikolanu has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Alan Ho
Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL 33136, USA
1 shared publication - Anat Galor
Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, USA
1 shared publication - Anne Shea1 shared publication
- Dilan Patel
Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL 33136, USA
1 shared publication - Kate MacDougall Saylor
University of Michigan Library, 1135 E. Catherine St, Ann Arbor, MI, 48109, USA
1 shared publication - Kathleen B. Digre
University of Utah
1 shared publication
Latest Publications
- 1 September 2026
- Published by Wolters Kluwer Health in Journal of Neuro-Ophthalmology
- Vol. 46 (3) , 301-316
A Scoping Review of Pharmacologic and Nonpharmacologic Interventions to Treat Chronic Ocular Pain
Background: Chronic ocular pain (COP) is disabling and a common reason for referral to neuro-ophthalmologists. Many patients with COP suffer from amplified or dysfunctional pain processing in the peripheral nervous system (PNS) or central nervous system (CNS), rather than a problem with the eye itself. The extent of and evidence for therapeutic interventions targeting pain in the PNS and CNS among patients suffering from COP are unknown. Evidence Acquisition: We performed a search of Ovid MEDLINE, Embase.com, Scopus.com, and ClinicalTrials.gov. We limited our search to English-language articles published since 2015. We included observational and experimental studies of pharmacologic and nonpharmacologic interventions (e.g., vagal nerve stimulation) used in adults 18 years or older with COP for at least 3 months. Studies were included if the impact on pain intensity, functioning, or quality of life was measured as primary, secondary, or exploratory outcomes. All articles were independently screened by 2 team members for inclusion. Data extraction was performed independently by 2 team members. Any disagreements during the screening and data extraction processes were adjudicated by a third team member and discussed as a group. Results: Our search identified 9,656 studies from 2015 to 2026. Of those, 21 met our inclusion/exclusion criteria. The study designs were mostly retrospective: 5 case reports, 9 observational, and 1 case–control study; 3 prospective studies were nonrandomized, observational studies. Three studies were randomized clinical trials, but one did not have published results. Most of the studies (67%, n = 14) were on pharmacologic interventions including all 3 completed prospective studies. Pharmacologic interventions included gabapentin, cryosim-3 applied to the eyelids, autologous serum tears, botulinum toxin Type A injections, and nerve blocks. The 6 studies including nonpharmacologic interventions used transcutaneous electrical nerve stimulation, trigeminal ganglion stimulation, and pulsed radiofrequency procedures. The 3 randomized controlled clinical trials were of transcutaneous electrical nerve stimulation, topical ocular cooling device, and topical OK-101 ophthalmic solutions at different concentrations. The most common pain measures used across the studies were pain intensity scales (range 0–10), such as the numeric rating scale. Improvements in COP were reported for most studies. The reporting of adverse events occurred in 8 studies (43%). Conclusions: Although COP is a common symptom, we found few studies on pharmacologic and nonpharmacologic treatment interventions with a few randomized controlled trials. Rigorous studies of treatment interventions aimed at reducing COP are needed. We provide recommendations for both the conduct of future studies and the current approach to COP treatment.
- 1 September 2026
- Published by Wolters Kluwer Health in Journal of Neuro-Ophthalmology
- Vol. 46 (3) , 301-316
A Scoping Review of Pharmacologic and Nonpharmacologic Interventions to Treat Chronic Ocular Pain
Background: Chronic ocular pain (COP) is disabling and a common reason for referral to neuro-ophthalmologists. Many patients with COP suffer from amplified or dysfunctional pain processing in the peripheral nervous system (PNS) or central nervous system (CNS), rather than a problem with the eye itself. The extent of and evidence for therapeutic interventions targeting pain in the PNS and CNS among patients suffering from COP are unknown. Evidence Acquisition: We performed a search of Ovid MEDLINE, Embase.com, Scopus.com, and ClinicalTrials.gov. We limited our search to English-language articles published since 2015. We included observational and experimental studies of pharmacologic and nonpharmacologic interventions (e.g., vagal nerve stimulation) used in adults 18 years or older with COP for at least 3 months. Studies were included if the impact on pain intensity, functioning, or quality of life was measured as primary, secondary, or exploratory outcomes. All articles were independently screened by 2 team members for inclusion. Data extraction was performed independently by 2 team members. Any disagreements during the screening and data extraction processes were adjudicated by a third team member and discussed as a group. Results: Our search identified 9,656 studies from 2015 to 2026. Of those, 21 met our inclusion/exclusion criteria. The study designs were mostly retrospective: 5 case reports, 9 observational, and 1 case–control study; 3 prospective studies were nonrandomized, observational studies. Three studies were randomized clinical trials, but one did not have published results. Most of the studies (67%, n = 14) were on pharmacologic interventions including all 3 completed prospective studies. Pharmacologic interventions included gabapentin, cryosim-3 applied to the eyelids, autologous serum tears, botulinum toxin Type A injections, and nerve blocks. The 6 studies including nonpharmacologic interventions used transcutaneous electrical nerve stimulation, trigeminal ganglion stimulation, and pulsed radiofrequency procedures. The 3 randomized controlled clinical trials were of transcutaneous electrical nerve stimulation, topical ocular cooling device, and topical OK-101 ophthalmic solutions at different concentrations. The most common pain measures used across the studies were pain intensity scales (range 0–10), such as the numeric rating scale. Improvements in COP were reported for most studies. The reporting of adverse events occurred in 8 studies (43%). Conclusions: Although COP is a common symptom, we found few studies on pharmacologic and nonpharmacologic treatment interventions with a few randomized controlled trials. Rigorous studies of treatment interventions aimed at reducing COP are needed. We provide recommendations for both the conduct of future studies and the current approach to COP treatment.
- Open Access
- 30 May 2026
- Published by MDPI AG in Antioxidants
- Vol. 15 (6) , 693
Polyphenol-Mediated Modulation of Oxidative Stress Pathways in Type 1 Diabetes: A Systematic Review
Oxidative stress is a central component of type 1 diabetes (T1D) pathophysiology, contributing to pancreatic β-cell vulnerability and the development of chronic complications. Current therapeutic strategies are primarily focused on glycemic control and do not directly address underlying redox imbalance. Dietary polyphenols, a structurally diverse class of plant-derived compounds, have been investigated for their antioxidant and cytoprotective properties, yet their role in T1D has not been systematically defined. This systematic review evaluates the effects of polyphenols on oxidative stress and glycemic parameters in preclinical models of T1D. Across studies, polyphenols were consistently associated with attenuation of oxidative stress, as evidenced by reductions in lipid peroxidation and reactive oxygen and nitrogen species, along with restoration of endogenous antioxidant defenses, including superoxide dismutase, catalase, and glutathione. These effects were frequently linked to modulation of redox-sensitive signaling pathways, particularly Nrf2-dependent mechanisms. In contrast, glycemic outcomes were heterogeneous and influenced by compound-specific and experimental factors. Modulation of oxidative stress markers was often observed independently of changes in glycemic parameters, suggesting a primary redox-mediated mode of action. These findings provide a mechanistic rationale for prioritizing oxidative-stress-focused endpoints in future translational studies and support the evaluation of polyphenols as adjunctive strategies targeting redox imbalance in T1D.
- 30 May 2026
- Published by MDPI AG in Antioxidants
- Vol. 15 (6) , 693
Open AccessPolyphenol-Mediated Modulation of Oxidative Stress Pathways in Type 1 Diabetes: A Systematic Review
Oxidative stress is a central component of type 1 diabetes (T1D) pathophysiology, contributing to pancreatic β-cell vulnerability and the development of chronic complications. Current therapeutic strategies are primarily focused on glycemic control and do not directly address underlying redox imbalance. Dietary polyphenols, a structurally diverse class of plant-derived compounds, have been investigated for their antioxidant and cytoprotective properties, yet their role in T1D has not been systematically defined. This systematic review evaluates the effects of polyphenols on oxidative stress and glycemic parameters in preclinical models of T1D. Across studies, polyphenols were consistently associated with attenuation of oxidative stress, as evidenced by reductions in lipid peroxidation and reactive oxygen and nitrogen species, along with restoration of endogenous antioxidant defenses, including superoxide dismutase, catalase, and glutathione. These effects were frequently linked to modulation of redox-sensitive signaling pathways, particularly Nrf2-dependent mechanisms. In contrast, glycemic outcomes were heterogeneous and influenced by compound-specific and experimental factors. Modulation of oxidative stress markers was often observed independently of changes in glycemic parameters, suggesting a primary redox-mediated mode of action. These findings provide a mechanistic rationale for prioritizing oxidative-stress-focused endpoints in future translational studies and support the evaluation of polyphenols as adjunctive strategies targeting redox imbalance in T1D.